Aquestive Therapeutics (NASDAQ:AQST) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report published on Wednesday,Benzinga reports. They currently have a $10.00 price target on the stock.

Several other analysts also recently weighed in on the company. Raymond James set a $7.00 price target on Aquestive Therapeutics in a research note on Friday, March 7th. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target for the company. Lake Street Capital dropped their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Finally, Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $10.57.

Aquestive Therapeutics Trading Up 6.3 %

Shares of Aquestive Therapeutics stock opened at $3.04 on Wednesday. Aquestive Therapeutics has a 12 month low of $2.24 and a 12 month high of $5.80. The firm has a market capitalization of $300.57 million, a P/E ratio of -6.76 and a beta of 2.76. The business has a fifty day simple moving average of $2.98 and a two-hundred day simple moving average of $3.91.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to the consensus estimate of $13.11 million. Analysts predict that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AQST. Price T Rowe Associates Inc. MD grew its holdings in shares of Aquestive Therapeutics by 16.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock worth $99,000 after acquiring an additional 3,821 shares during the period. MetLife Investment Management LLC grew its stake in shares of Aquestive Therapeutics by 11.4% during the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company’s stock valued at $143,000 after purchasing an additional 4,125 shares during the period. Bank of Montreal Can lifted its stake in shares of Aquestive Therapeutics by 10.1% in the 4th quarter. Bank of Montreal Can now owns 54,300 shares of the company’s stock worth $193,000 after purchasing an additional 4,999 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Aquestive Therapeutics by 3.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company’s stock worth $750,000 after buying an additional 7,129 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in Aquestive Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after buying an additional 7,347 shares during the period. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.